Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers  

作　　者：Zhihao Lu Mingfei Geng Yongtao Han Jianzhong Cao Jun Wang Tianshu Liu Xianglin Yuan Xue Meng Yanqiao Zhang Rong Zhao Lixin Wan Enxiao Li Wenran Wang Zhijie Li Danfeng Shi Jing Qian Si Shi Fengshi Dong Lin Shen 

机构地区：[1]Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Gastrointestinal Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China [2]Department of Thoracic Surgery,Anyang Cancer Hospital,Anyang 455001,China [3]Department of Thoracic Surgery,Sichuan Cancer Hospital,Chengdu 610042,China [4]Department of Radiotherapy,Shanxi Provincial Cancer Hospital,Taiyuan 030013,China [5]Department of Radiotherapy,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China [6]Department of Medical Oncology,Zhongshan Hospital,Fudan University,Shanghai 200032,China [7]Department of Medical Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China [8]Department of Radiotherapy,Shandong Cancer Hospital,Jinan 250117,China [9]Department of Gastroenterology,Harbin Medical University Cancer Hospital,Harbin 150081,China [10]Department of Pharmacy,Affiliated Hospital of Jiangsu University,Zhenjiang 212001,China [11]Department of Medical Oncology,Nanyang Central Hospital,Nanyang 473005,China [12]Department of Medical Oncology,The First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China [13]Department of the Cancer Center,The First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,China [14]Department of Thoracic Surgery,Weifang Second People’s Hospital,Weifang 261041,China [15]Value&Implementation,Global Medical&Scientific Affairs,MSD China,Shanghai 200233,China [16]State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers,Beijing Key Laboratory of Carcinogenesis and Translational Research,Department of Gastrointestinal Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China

出　　处：《Cancer Biology & Medicine》2024年第12期1171-1184,共14页癌症生物学与医学(英文版)

基　　金：This support was funded by MSD China.

摘　　要：Objective:Esophageal cancer(EC)ranks eighth among cancers in cancer-related deaths globally,and~44%of new cases occur in China.We sought to describe the clinical characteristics and treatment landscape of EC in China before the approval of immunotherapy in 2020.Methods:CHANNEL was a large,retrospective study using patient-level data from 14 hospitals/cancer centers across China,including adults initiating therapy for newly diagnosed EC(January to December 2018).Demographics,clinicopathologic characteristics,and treatment patterns over 6 months were descriptively summarized.Results:Of 3,493 patients,75.7%were men,the mean age was 64.1 years,and 75.0%had no family history of cancer.Most(92.8%)had squamous cell carcinoma,with a primary lesion in the middle esophagus(56.4%).Among patients with resectable EC,92.9%received initial surgery,and 7.1%received neoadjuvant therapy,primarily chemotherapy(85.5%platinum-taxane).Among patients with unresectable early or locally advanced EC,50.8%and 49.2%received palliative and radical therapy,respectively,as the initial treatment,primarily chemotherapy(66.5%platinum-taxane)and chemoradiotherapy(50.8%platinum-taxane),respectively.Adjuvant therapy was administered to 22.9%of patients undergoing initial surgery,and 2.4%receiving neoadjuvant therapy and surgery.Among patients with advanced EC,84.6%received systemic therapy as an initial treatment,primarily chemotherapy(61.5%platinum-taxane).Conclusions:Before the approval of immunotherapy in China,most patients with resectable early or locally advanced EC underwent radical surgery without preoperative treatment,whereas most patients with advanced EC received platinum-taxane chemotherapy.These findings highlight the need for novel EC treatments before immunotherapy was introduced,and provide a baseline for evaluating the benefits of immunotherapy,now that this treatment is widely used in this setting.

关 键 词：Esophageal cancer China clinicopathologic characteristics treatment landscape RETROSPECTIVE 

分 类 号：R735.1[医药卫生—肿瘤]